GHRH analogue peptide

CJC-1295

US: Not on the registerEU: Not on the registerUK: Not on the registerCA: Not on the registerAU: Status unknownCH: Not on the registerBR: Not on the registerRS: Not on the registerSG: Not on the registerTR: Not on the register

Answer

CJC-1295 is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. No trial states a phase. It has 1 registered trial, 0 of them running.

RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov, read 2026-08-31

Not medical, legal or regulatory advice.

Registered trials1Trial register ClinicalTrials.gov

Running now0Trial register recruiting, active or enrolling

Results posted0Trial register with results on the register

Stopped early100%Trial register all peptides: 10%

1 trials by status

Trial register

Stopped early 1

ClinicalTrials.gov · read 2026-08-31 · 0 trials have posted results

Trials first submitted per year

Trial register

12005

ClinicalTrials.gov first-submitted date, last 1 years · read 2026-08-31.

Status by jurisdiction

World map

CAISNOUSUKEUUACNKRJPMXCHLIRSTRINTHBREGILSAAESGARZAAUNZ

Authorised or registeredNot on the register, or withdrawnNot read yet, or status unknown

Where	Status	Register	Read
United States	Not on the register	FDA, openfda	2026-10-03
European Union	Not on the register	EMA, ema	2026-08-31
United Kingdom	Not on the register	MHRA, uk-mhra	2026-09-03
Canada	Not on the register	Health Canada, ca-dpd	2026-09-03
Australia	Status unknown	TGA, au-artg	not read
Switzerland	Not on the register	Swissmedic, ch-swissmedic	2026-09-03
Brazil	Not on the register	ANVISA, br-anvisa	2026-09-03
Serbia	Not on the register	ALIMS, rs-alims	2026-09-03
Singapore	Not on the register	HSA, sg-hsa	2026-09-03
Turkey	Not on the register	TITCK, tr-titck	2026-09-03

An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.

CHANGE ALERTS

Get an email when this changes

One email when the status of CJC-1295 changes on the register. You confirm your address first.

ENFORCEMENT AND OFFICIAL ACTIONS

2 actions by named authorities

Enforcement actions, board positions and payer rules that name CJC-1295, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.

US-OHenforcement

Ohio Board of Pharmacy, 2026-04-16

During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: u. CJC-1295 w/ DAC, 5 vials;

State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraph 2(u) · quoted with the party redacted

US-CAenforcement

California Board of Pharmacy, 2023-12-04

CJC-1295 a synthetic product consisting of 30 amino acids, and is therefore a peptide. It is a dangerous drug pursuant to Code section 4022.

California Board of Pharmacy, First Amended Accusation and First Amended Statement of Issues, Case Nos. 7160 and 7171, paragraph 30

REGISTERED TRIALS

1 trial, newest first

NCT00267527	A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity terminated before completion · register updated 2006-10-16

All peptides · Method

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.